## I-Tsu Chyuan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1726351/publications.pdf Version: 2024-02-01



LTSU CHVUAN

#	Article	IF	CITATIONS
1	New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochemical Pharmacology, 2020, 175, 113928.	4.4	51
2	Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Cells, 2019, 8, 963.	4.1	50
3	Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. Biochemical Pharmacology, 2021, 193, 114760.	4.4	42
4	Lovastatinâ€mediated MCFâ€7 cancer cell death involves LKB1â€AMPKâ€p38MAPKâ€p53â€survivin signalling ca Journal of Cellular and Molecular Medicine, 2020, 24, 1822-1836.	ascade. 3.6	40
5	TRAIL-Mediated Suppression of T Cell Receptor Signaling Inhibits T Cell Activation and Inflammation in Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2018, 9, 15.	4.8	35
6	Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis. Journal of Molecular Medicine, 2016, 94, 545-556.	3.9	34
7	An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis. Cellular and Molecular Immunology, 2018, 15, 846-857.	10.5	34
8	Shaping of Innate Immune Response by Fatty Acid Metabolite Palmitate. Cells, 2019, 8, 1633.	4.1	34
9	Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice. Rheumatology, 2015, 54, 1317-1326.	1.9	32
10	Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	30
11	Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cellular and Molecular Immunology, 2015, 12, 317-325.	10.5	28
12	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers, 2021, 13, 1188.	3.7	27
13	TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment. Cell Death and Disease, 2019, 10, 77.	6.3	25
14	Significant association of rheumatoid arthritis-related inflammatory markers withÂnon-surgical periodontal therapy. Journal of the Formosan Medical Association, 2018, 117, 1003-1010.	1.7	22
15	β2â€Glycoprotein lâ€Dependent Antiâ€Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. Journal of Periodontology, 2015, 86, 995-1004.	3.4	20
16	Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cellular and Molecular Immunology, 2021, 18, 1772-1782.	10.5	14
17	Tumor necrosis factor: The key to hepatitis B viral clearance. Cellular and Molecular Immunology, 2018, 15, 731-733.	10.5	12
18	Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation. Cancers, 2021, 13, 1253.	3.7	11

#	Article	IF	CITATIONS
19	TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases. Cellular and Molecular Immunology, 2020, 17, 1281-1283.	10.5	9
20	Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications. Journal of the Formosan Medical Association, 2021, 120, 1667-1675.	1.7	7
21	T Cell–Specific Deletion of TRAIL Receptor Reveals Its Critical Role for Regulating Pathologic T Cell Activation and Disease Induction in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2022, 208, 1534-1544.	0.8	0